

**Supplementary Table S1.** Main studies focused on the characterisation of young-onset primary SS.

| First author        | Year | Country | Age criteria | Number of patients | Gender (F) | Sicca symptoms                                                                                                                                                | Oral tests                                                                                                                                                                                                                                | Ocular tests                                                                                                                                                                                                                                                                     | Salivary biopsy                                                                                                                                              | Autoantibodies                                                                                                                                                                                                                                                                                                                                                                                                                      | Systemic disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------------------|------|---------|--------------|--------------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Ramos-Casals</b> | 1998 | Spain   | < 35 years   | 13                 | 13         | Xerostomia n=12 (92%); Xerophthalmia n=12 (92%) (not detailed)                                                                                                | NA                                                                                                                                                                                                                                        | Positive Schirmer's eye test and/or rose Bengal staining n=13 (100%) (not detailed)                                                                                                                                                                                              | Lymphocytic infiltrates grade 3 or 4 in 9 out of 11 (82%) (not detailed)                                                                                     | ANA n= 8 (62%), RF n= 9 (70%), anti-Ro=SS-A n= 9 (70%); anti-La=SS-B n= 4 (31%). Compared with patients with older onset ( $\geq 35$ years), young onset had a higher prevalence of RF (70% vs. 39%, $p=0.034$ ), anti-Ro=SS-A antibodies (70% vs. 28%, $p=0.004$ ) and monoclonal immunoglobulins (23% vs. 4%, $p=0.02$ ) in their sera.                                                                                           | Articular (31%), peripheral neuropathy (23%), cutaneous vasculitis (23%) and Raynaud's phenomenon (23%). Patients with a younger onset vs. older onset ( $\geq 35$ years), presented a higher prevalence of lymphadenopathy (54% vs. 6%, $p<0.001$ , OR 17.9, CI 4.1±81.8). The prevalence of recurrent parotidomegaly or splenomegaly were also more common in patients with a young onset but NS. Young onset developed lymphoproliferative disease, compared with one patient of the older-onset group (23% vs. 1%, $p=0.002$ , OR 39, IC 3.1±1976.2). |
| <b>Haga</b>         | 1999 | Norway  | < 45 years   | 16                 | NA         | NA                                                                                                                                                            | Unstimulated whole sialometry showed normal values in 31 pts. (Not detailed)                                                                                                                                                              | Schirmer I and UWS correlated to s-IgG ( $p<0.01$ ), anti-SSA/SSB ( $p<0.02$ ), and RF ( $p<0.05$ ). The combination of ANA, anti-SSA/SSB and RF correlated to the surface index ( $p<0.02$ ), but not to any of the other indices for disease manifestations in young patients. | Positive biopsy minor salivary glands 80%. The frequency of positive biopsy of the minor salivary glands was high, but NS different in the three age groups. | ANA (87.5%); Anti-SSA/SSB (62.5%); RF (62.5%); presence of ANA, anti-SSA/SSB (50%). The age at diagnosis (<45 years) correlated to the presence of the serological parameters anti-SSA/SSB ( $p<0.02$ ), RF ( $p<0.01$ ), s-IgG ( $p<0.05$ ) and so did the presence of the combination of ANA, anti-SSA/SSB and RF ( $p<0.02$ ) compared to patients to middle aged (diagnosed 45 - 60 years) and old patients ( $\geq 60$ years). | Raynaud's phenomenon in 50% of $\leq 45$ years compared to 41.2% in $\geq 45$ years; the difference being not NS. Arthritis was 12.5% and 9.8%, respectively (NS).                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Ramos-Casals</b> | 2008 | Spain   | <35 years    | 137                | NA         | Lower xerostomia compared with those aged >35 years                                                                                                           | NA                                                                                                                                                                                                                                        | Lower positive ocular tests compared with those aged >35 years                                                                                                                                                                                                                   | NA                                                                                                                                                           | Higher prevalence of immunologic markers (RF >25 UI/L = 83/132 (63%), Anti-Ro/SS-A (+)= 101/135 (75%), Anti-La/SS-B (+)= 68/135 (50%)) were found in patients aged <35 years compared with those aged >35 years.                                                                                                                                                                                                                    | Higher prevalence of vasculitis n= 21(15%) in younger compared with those aged >35 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Botsios</b>      | 2011 | Italy   | < 40 years   | 130                | 127 (98)   | Xerostomia<br><br>xerophthalmia n= 102 (78.5). NS between three groups: elderly (> 65 years), adult (> 40 and $\leq 65$ years), and young ( $\leq 40$ years). | UWSF ( $\leq 1.5$ mL n= 94 (72.3); n= 78 (60); salivary sialography (score $\geq 1$ according to Rubin e Holt) n= 88 (67.6). NS between three groups elderly (> 65 years), adult (>40 and $\leq 65$ years), and young ( $\leq 40$ years). | Schirmer I test in 15 minutes) Rose-Bengal (score $\geq 4$ ) n= 43 (33.3). NS between three groups: elderly (> 65 years), adult (> 40 and $\leq 65$ years), and young ( $\leq 40$ years).                                                                                        | Focus score n= 86 (66.1); NS between three groups: elderly (> 65 years), adult (> 40 and $\leq 65$ years), and young ( $\leq 40$ years).                     | ANA + (titre $\geq 1$ n= 71(64.5). (92.8); Anti-Ro+ n= 109 (83.9); anti-La+ n= 82 (63); RF > 40 IU/L n= 95 (75.8) NS between three groups: elderly (> 65 years), adult (> 40 and $\leq 65$ years), and young ( $\leq 40$ years).                                                                                                                                                                                                    | Arthralgia n= 96 (73.9); > 1:80 n= 117 arthritis n= 48 (36.9); Raynaud's phenomenon n= 34 (26.1), lymphadenopathy n=28 (21.5); purpura n= 29 (22.3). NS between three groups: elderly (> 65 years), adult (> 40 and $\leq 65$ years), and young ( $\leq 40$ years).                                                                                                                                                                                                                                                                                       |

| First author | Year | Country | Age criteria | Number of patients | Gender (F) | Sicca symptoms                                                                                                                                              | Oral tests | Ocular tests | Salivary biopsy | Autoantibodies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Systemic disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|--------------|------|---------|--------------|--------------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Theander     | 2015 | Sweden  | <40 years    | 23                 | NA         | NA                                                                                                                                                          | NA         | NA           | NA              | In 23 patients, primary SS was diagnosed before age 40. These patients showed a significantly higher prevalence of pre-diagnostic autoantibodies (ANAs, RF, and autoantibodies against Ro 60/SSA, Ro 52/SSA, and La/SSB) compared with those ages 40–60 years (n=56) or 60 years (n=38) at diagnosis. The prevalence of autoantibodies after diagnosis was also higher in patients with early-onset disease than in those with late-onset disease RF ( $p=0.044$ and $p=0.028$ for patients with early-onset disease vs 40 and 60 years and vs. older than 60, respectively), and Ro 60/SSA ( $p=0.001$ for both comparisons), Ro 52/SSA ( $p=0.029$ and $P50.006$ ), and La/SSB ( $p=0.020$ and $p=0.007$ ), but not for ANAs. | NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Zhao         | 2015 | China   | <35 years    | 75 (5.3%)          | NA         | Sicca symptoms, n (%) 46/72 (63.9); xerophthalmia, n (%) 10 (37.0) were observed less frequently.                                                           | NA         | NA           | NA              | Higher prevalence of high IgG levels and low C3 levels were found at diagnosis in <35 years compared with > 35 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Purpura, n (%) 24/349 (6.9); flaccid paralysis due to hypokalemia n=17/373 (4.6), flaccid paralysis due to hypocytosis, n (%) 33/373 (8.8). Higher prevalence of purpura and flaccid paralysis resulting from hypokalemia and pancytopenia were found at diagnosis in <35 years compared with > 35 years.                                                                                                                                                                                  |
| Nakanishi    | 2016 | Japan   | <60 years    | 87                 | 83 (95%)   | Xerostomia, n (%) 42 (51%); Xerophthalmia = 34 (41%). Compared to the younger age group (<60 years), the older patients were more likely to have dry mouth. | NA         | NA           | NA              | Anti-SSA antibodies and or anti-SSB antibodies n= 82 (94%); ANA > 1/320 n= 30 (39%); RF n=26 (55%). NS compared with < 60 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Arthritis n=12 (11%); PN n=6 (6.9%); aseptic meningitis n=4 (4.6%); lymphoma n=2 (2.3%) vs. n=7 (12) elderly 1/320 n= 30 (39%); $p=0.03$ . The younger patients had a greater likelihood of arthritis and a photosensitive rash ( $p<0.05$ ).                                                                                                                                                                                                                                              |
| Anquetil     | 2019 | France  | <35 years    | 55                 | NA         | Xerostomia 21/55 (38.2) NS; Xerophthalmia 28/44 (63.6) NS compared with age >35 years.                                                                      | NA         | NA           | NA              | ANA younger was 86.5% vs. 73.1% for the later onset group ( $p = 0.038$ ), 84.6% presented anti-SSA vs. 54.4% ( $p<0.001$ ) and 57.7% presented anti-SSB vs. 29.7% ( $p<0.001$ ). RF was positive in 41.5% vs. 20.2% ( $p<0.001$ ). Anti-SSA antibodies was statistically associated with early-onset pSS (OR= 3.23, 95% CI 1.43, 7.31).                                                                                                                                                                                                                                                                                                                                                                                        | Higher frequency of adenopathy (25.5% vs. 11.8%, $p = 0.006$ ), purpura (23.6% vs. 9.2%, $p = 0.002$ ) and renal involvement (16.4% vs. 4.4%, $p = 0.003$ ) compared with age >35 years. ESSDAI NS at diagnosis. The variation in ESSDAI scores between baseline and the 5-year follow-up was significant ( $p = 0.005$ ). Significant improvement in ESSDAI scores (-1.27, $p<0.001$ ) in the later onset group and a trend for aggravation in the early-onset group (0.72, $p = 0.27$ ). |

| First author | Year | Country     | Age criteria | Number of patients | Gender (F) | Sicca symptoms                                                                                                                                                                                                                          | Oral tests                                                                                                                                                  | Ocular tests                                                    | Salivary biopsy                          | Autoantibodies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Systemic disease                                                                                                                                                                                                                                                                 |
|--------------|------|-------------|--------------|--------------------|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Lee          | 2021 | South Korea | < 40 years   | 23                 | 21 (91.3)  | Xerostomia, n (%) 21 (91.3); xerophthalmia, n (%) 17 (73.9) NS between EopSS ( $\geq 65$ years), adult-onset (AopSS) ( $\geq 40$ and < 65 years), and young-onset (YopSS) (< 40 years).                                                 | USFR, ml/minute 0.18 (0.03, 0.36); SGUS score $\geq 14$ was significantly higher in the young (78.3%) ( $p < 0.05$ ) compared with EopSS ( $\geq 65$ years) | Abnormal Schirmer's test, n (%) 12 (52.2) NS with elderly group | Focus score 1 (1, 2) NS between 3 groups | ANA $\geq 1:160$ , n (%) 18 (78.3); anti-Ro/SSA, n (%) 22 (95.7); anti-La/SSB, n (%) 12 (52.2); RF, IU/dl 31.5 (14.3, 54.5). YopSS had higher positivity of anti-Ro/SSA and anti-La/SSB compared to those with EopSS and AopSS.                                                                                                                                                                                                                                                                                                                                                | Patients with YopSS had a significantly higher frequency of arthritis (39.1%, 7% and 22.6%, respectively, $p < 0.01$ ) than those with EopSS and AopSS.                                                                                                                          |
| Alunno       | 2021 | Italy       | < 40 years   | 64                 | 60 (94)    | Xerostomia < 40 years n=56 (87%) vs. $\geq 40$ and < 65 n=142 (84%) vs. Onset $\geq 65$ years n= 44 (80%) $p=$ NS. Xerophthalmia < 40 years n=57 (89%) vs. $\geq 40$ and < 65 n=145 (86%) vs. Onset $\geq 65$ years n= 48 (87%) $p=$ NS | NA                                                                                                                                                          | NA                                                              | NA                                       | Neither anti-Ro nor anti-La < 40 years n= 10 (16%) vs. $\geq 40$ and < 65 n=52 (31%) vs. Onset $\geq 65$ years n= 28 (51%) NS; Anti-Ro only < 40 years n= 15 (23%) vs $\geq 40$ and < 65 n= 63 (37%) vs. $\geq 65$ years n= 17 (31%) NS; Anti-La only < 40 years n= 1 (1.5%) vs. $\geq 40$ and < 65 n= 4 (2%) vs. $\geq 65$ years n= 1 (2%) NS; both anti-Ro and anti-La < 40 years n= 29 (45%) vs $\geq 40$ and < 65 n= 49 (29%) vs. $\geq 65$ years n= 18 (33%) NS; RF < 40 years n=35 (55%) vs. $\geq 40$ and < 65 n= 74 (44%) vs. $\geq 65$ years n= 20 (36%) $p < 0.01$ . | Articular manifestations n= 32 (50); purpura n= 1 (1.5); Raynaud's phenomenon n=15 (23); pulmonary manifestations n= 4 (6); cardiac manifestations n= 2 (3); cutaneous manifestations n= 5 (8); PNS manifestations n= 2 (3) NS vs. $\geq 40$ and < 65) vs. onset $\geq 65$ years |

**Supplementary Table S2.** Main studies focused on the characterisation of elderly-onset primary SS.

| First author           | Year | Country | Age criteria | Number of patients | Gender (F) | Sicca symptoms                                                                                                                                              | Oral tests                                                                                                                                                                     | Ocular tests                                                                                                                                                   | Salivary biopsy                                                                                                                                                                                            | Autoantibodies                                                                                                                                                                                                                                                      | Systemic disease                                                                                                                                                                                                                                                                                                                                                                             |
|------------------------|------|---------|--------------|--------------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>García-Carrasco</b> | 1999 | Spain   | > 70 years   | 31 (14%)           | 26         | Xerostomia, n (%) =30 (97%); Xerophthalmia n= 28 (90%). NS compared with onset <70 y                                                                        | NA                                                                                                                                                                             | NA                                                                                                                                                             | Lymphocytic infiltrates grade 3 or 4 (Chisholm ± Mason classification) in 15 (71%) out of 21 patients. NS compared with onset <70 y                                                                        | ANA n= 20 (64%); RF n= 11 (38%), anti-Ro=SSA n= 5 (17%), anti-La=SSB n= 5 (17%). NS compared with onset <70 y                                                                                                                                                       | Articular involvement (29%), hepatic involvement (20%), peripheral neuropathy (16%) and interstitial pneumopathy (13%). NS compared with onset <70 y                                                                                                                                                                                                                                         |
| <b>Tishler</b>         | 2001 | Israel  | ≥ 65 years   | 17                 | 16         | Xerostomia n=17 (100%); Xerophthalmia n=16 (94) NS between <65 vs. > 65 years                                                                               | NA                                                                                                                                                                             | NA                                                                                                                                                             | NA                                                                                                                                                                                                         | ANA n=6 (36); anti-Ro(SSA) n= 2 (12); anti-La(SSB) n= 2 (12); RF n=2 (12) . RF and anti-Ro(SSA) antibodies were more common in the YOD group ( $p = 0.012$ and $p = 0.023$ , respectively).                                                                         | Raynaud's n= 2 (12); articular involvement n=3 (18). NS differences were noted in the clinical disease manifestations between the 2 groups of patients (<65 vs. > 65 years)                                                                                                                                                                                                                  |
| <b>Ramos-Casals</b>    | 2008 | Spain   | > 70 years   | 156                | NA         | NA                                                                                                                                                          | NA                                                                                                                                                                             | NA                                                                                                                                                             | NA                                                                                                                                                                                                         | A lower frequency of Anti-Ro/SS-A (+) = 61/156 (39%) was found in patients aged > 70 years compared with those aged < 70 years                                                                                                                                      | Lower frequency of arthralgia, Raynaud's phenomenon and a higher prevalence of pulmonary involvement 26 (17%) were found in patients aged > 70 years compared with those aged < 70 years                                                                                                                                                                                                     |
| <b>Botsios</b>         | 2011 | Italy   | ≥ 65 years   | 21 (6%)            | 20 (95%)   | Xerostomia, n (%) 15 (71.4%); Xerophthalmia= 16 (76.1%). NS between three groups: elderly (> 65 years), adult (> 40 and ≤65 years), and young (≤40 years).  | UWSF showed normal values; positivity for salivary sialography n=12 (57.1%). NS between three groups: elderly (> 65 years), adult (> 40 and ≤65 years), and young (≤40 years). | Schirmer's I n= 17 (80%); Rose-Bengal staining n= 9 (44.4%). NS between three groups: elderly (> 65 years), adult (> 40 and ≤65 years), and young (≤40 years). | A focus score greater or equal to 1 per 4mm <sup>2</sup> was demonstrated in 11 (53.3%) of the 21 cases. NS between three groups: elderly (> 65 years), adult (> 40 and ≤65 years), and young (≤40 years). | ANA n=18 (85.7%); RF n= 15 (71.1%), anti-Ro n= 14 (66.7%), anti-La n= 11 (52.3%). NS between three groups: elderly (> 65 years), adult (> 40 and ≤65 years), and young (≤40 years).                                                                                 | Arthralgias n= 14 (66.7%), Raynaud's phenomenon n= 5 (23.8%); purpura n= 3 (14.2%). NS between three groups: elderly (> 65 years), adult (> 40 and ≤65 years), and young (≤40 years).                                                                                                                                                                                                        |
| <b>Chebbi</b>          | 2015 | Tunisia | ≥ 65 years   | 18                 | 17 (94.5%) | Xerostomia n=18 (100); Xerophthalmia n=18 (100); Keratoconjunctivitis sicca n=12 (66.6%). NS between elderly vs. ≤ 65 years                                 | Salivary gland scintigraphy, performed in 16 patients, revealed poor uptake of the salivary glands in 15 cases (93.7%). NS between elderly vs. ≤ 65 years                      | Abnormal Schirmer's test, n (%) 18 (100). NS between elderly vs. ≤ 65 years                                                                                    | Stage III or IV of the Chisholm classification in 88.8% of cases. NS between elderly vs. ≤ 65 years                                                                                                        | ANA elderly n=8 (44.4%) vs. ≤ 65 years N= 34 (80.9%) $p= 0.005$ , anti-SSA elderly n=6 (33.3%) vs. ≤ 65 years N= 29 (69%) $p= 0.01$ and anti-SSB antibodies elderly n=3 (16.6%) vs. ≤ 65 years N= 19 (45.2%) $p= 0.035$ were significantly higher in young subjects | Extra-glandular manifestations n= 17 (94.5%). Joint involvement n= 16 (88.8%) (arthralgias n= 15, arthritis n=1). Neuropsychiatric manifestations n=7 (38.8%). PNS n= 6 (33.3%). CNS n= 5 (27.7%). Lung involvement n= 8 patients (44.4%). Renal impairment of distal tubular acidosis n= 2 (11.1%). Purpura n= 1. Pulmonary in the elderly n=8 (44.4%) vs. ≤ 65 years n=6 (14.2%) $p=0.019$ |
| <b>Nakanishi</b>       | 2016 | Japan   | ≥ 60 years   | 60 (41%)           | 51 (91%)   | Xerostomia, n (%) 42 (79%); Xerophthalmia = 24 (45%). Compared to the younger age group (<60 years), the older patients were more likely to have dry mouth. | NA                                                                                                                                                                             | NA                                                                                                                                                             | NA                                                                                                                                                                                                         | Anti-SSA antibodies and or anti-SSB antibodies n= 53 (88%); ANA > 1/320 n= 23 (44%); RF n=20 (56%). NS compared with < 60 years                                                                                                                                     | ILD n= 4 (6.7%); CBP n=13 (22%); lymphoma n=7 (12) s vs. younger n=2 (2.3%) $p=0.03$ . Compared to the younger age group, the older patients were more likely to have primary biliary cirrhosis, lymphoma and thrombocytopenia.                                                                                                                                                              |

| First author   | Year | Country     | Age criteria | Number of patients | Gender (F) | Sicca symptoms                                                                                                                                                                                                                                                           | Oral tests                                                                                                                                                         | Ocular tests                                                                                                                                                                                                                                                            | Salivary biopsy                                                                        | Autoantibodies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Systemic disease                                                                                                                                                                                                                                                                                        |
|----------------|------|-------------|--------------|--------------------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Lacombe</b> | 2020 | France      | ≥ 50 years   | 105                | NA         | Subjective DES < 50 years old n=40 (95.2%) vs. ≥ 50 years old n=95 (90.5%) < 0.01<br>UWS flow (mL/min) 0.20 [0.07–0.33]; UWS flow rate ≤ 0.1 mL/min n= 40 (38.1%). UWS had poor diagnostic performances whatever the threshold in the women ≥ 50 group.                  | UWS flow (mL/min) 0.20 [0.07–0.33]; UWS flow rate ≤ 0.1 mL/min n= 40 (38.1%). UWS had poor diagnostic performances whatever the threshold in the women ≥ 50 group. | Schirmer (mm/5 min) < 50 years n=5 [1–17.3] vs. ≥ 50 years n=1 [0–4] < 0.001. Schirmer ≤ 5 mm/5 min < 50 years n= 25 (59.5%) vs. ≥ 50 years n= 90 (85.7%) < 0.001. OSS ≥ 5 (if examination was realized) < 50 years n= 2/10 (20.0%) vs. ≥ 50 years n= 8/29 (27.6%) 0.51 | Focus score ≥ 1 on MSGB < 50 years n= 17 (40.5%) vs. ≥ 50 years n= 61 (58.1%) p= 0.051 | Anti-SSA antibodies < 50 years n= 9 (21.4%) vs. ≥ 50 years n=22 (21.0%) p=0.35; Anti-SSB antibodies < 50 years n= 6 (14.3%) vs. ≥ 50 years n=16 (15.2%) p=0.95; ANA > 1/200 < 50 years n=12 (28.6%) vs. ≥ 50 years n= 32 (30.5%) p=0.96                                                                                                                                                                                                                                                                                     | NA                                                                                                                                                                                                                                                                                                      |
| <b>Lee</b>     | 2021 | South Korea | ≥ 65 years   | 43 (19.5%)         | 40 (93.0%) | Xerostomia, n (%) 40 (93.0) NS with younger group; Xerophthalmia= 35 (81.4) ND. The duration of sicca symptoms in the EopSS (≥ 65 years) was shorter than in the adult-onset (AopSS) (≥ 40 and < 65 years), (p < 0.001) and young-onset (YopSS) (< 40 years) (p < 0.05). | USFR, ml/minute 0.1 (0, 0.25); SGUS score ≥ 14 was significantly lower in the elderly (44.2%) than in the AopSS (64.5%) and YopSS (78.3%) (p < 0.05) groups        | Abnormal Schirmer's test, n (%) 25 (58.1) NS between 3 groups                                                                                                                                                                                                           | Focus score (1, 1.75) NS between 3 groups                                              | EopSS had significantly lower positivity of anti-Ro/SSA and anti-La/SSB compared to those with AopSS and YopSS. A                                                                                                                                                                                                                                                                                                                                                                                                           | EopSS had significantly higher frequency of ILD (51.2% vs. 13.5% and 8.7%, respectively, p < 0.001) and lower frequency of arthritis (7% vs. 22.6%, and 39.1%, respectively, p < 0.01) than those with AopSS and YopSS. ESSDAI was significantly higher in EopSS than in opSS (3 vs. 2, p < 0.01).      |
| <b>Alunno</b>  | 2021 | Italy       | ≥ 65 years   | 55                 | 55         | Xerostomia < 40 years n=56 (87%) vs. ≥ 40 and < 65 n=142 (84%) vs. onset ≥ 65 years n= 44 (80%) p= NS. Xerophthalmia < 40 years n=57 (89%) vs. ≥ 40 and < 65 n=145 (86%) vs. onset ≥ 65 years n= 48 (87%) p= NS                                                          | NA                                                                                                                                                                 | NA                                                                                                                                                                                                                                                                      | NA                                                                                     | Neither anti-Ro nor anti-La < 40 years n= 10 (16%) vs. ≥ 40 and < 65 n=52 (31%) vs. onset ≥ 65 years n= 28 (51%) NS; Anti-Ro only < 40 years n= 15 (23%) vs. ≥ 40 and < 65 n= 63 (37%) vs. ≥ 65 years n= 17 (31%) NS; Anti-La only < 40 years n= 1 (1.5%) vs. ≥ 40 and < 65 n= 4 (2%) vs. ≥ 65 years n= 1 (2%) NS; both anti-Ro and anti-La < 40 years n= 29 (45%) vs. ≥ 40 and < 65 n= 49 (29%) vs. ≥ 65 years n= 18 (33%) NS; RF < 40 years n=35 (55%) vs. ≥ 40 and < 65 n= 74 (44%) vs. ≥ 65 years n= 20 (36%) p < 0.01. | Articular manifestations n=36 (65); purpura n= 6 (11); Raynaud's phenomenon n= 9 (14); pulmonary manifestations n= 4 (7), cardiac manifestations n= 3 (5), cutaneous manifestations n= 10 (18), liver manifestations n= 2 (4); PNS manifestations n= 6 (11) NS vs. ≥ 40 and < 65) vs. onset ≥ 65 years. |